Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
March 15 2018 - 7:30AM
Minerva Neurosciences, Inc. (Nasdaq:NERV), a biopharmaceutical
company focused on the development of therapies to treat central
nervous system (CNS) disorders, today announced that it will host a
Key Opinion Leader (KOL) meeting on the topic of Negative Symptoms
of Schizophrenia on Thursday, March 22, 2018 in New York City.
The event will feature presentations by KOLs Ofer Agid, MD,
Centre for Addiction and Mental Health, University of Toronto, and
Thomas Laughren, MD, former Division Director, Division of
Psychiatry Products, CDER, who will discuss the current
pharmacological treatment strategies to address positive and
negative symptoms of schizophrenia, as well as the regulatory path
for novel compounds that address negative symptoms. Both Dr. Agid
and Dr. Laughren will be available to answer questions at the
conclusion of the event.
Members of Minerva's management team will further discuss the
evolving paradigm in the diagnosis and pharmacological treatment of
negative symptoms in schizophrenia and beyond. They will review the
clinical development of roluperidone (MIN-101) for the treatment of
negative symptoms of schizophrenia and the design of the Phase 3
clinical trial with this compound.
Dr. Agid is a Clinician Scientist and Psychiatrist in the
Schizophrenia Program and Medical Leader of the Home Intervention
for Psychosis (HIP) team at the Centre for Addiction and Mental
Health. He is also Associate Professor in the Department of
Psychiatry at the University of Toronto. Dr. Agid’s research focus
is psychopharmacology in schizophrenia, specifically early response
to antipsychotic medications and early predictors of response. His
work has uncovered a new “early onset of action” hypothesis of
antipsychotics, which has impacted current practice guidelines for
the treatment of schizophrenia. As the medical leader of the HIP
team, Dr. Agid initiated an algorithm-based treatment approach for
first-episode schizophrenia while collecting extensive clinical
data regarding treatment response. This algorithm was implemented
in order to optimize antipsychotic treatment during the earliest
stages of the illness, a critical time period in terms of
longer-term outcomes. This systematic and standardized approach has
resulted in a large and comprehensive database; the published data
to date have provided clear, empiric evidence that clinicians can
use in approaching the pharmacological management of first-episode
schizophrenia. It has also challenged current practice patterns and
proven valuable in examining trajectories of response. In addition,
Dr. Agid is involved in investigating patterns of non-adherence and
examining value systems and happiness in schizophrenia, with an
emphasis on the relationship to, and influence on, functional
outcomes.
Dr. Laughren is currently a consultant in psychiatric drug
development. He recently retired as Division Director for the
Division of Psychiatry Products, Center for Drug Evaluation and
Research at FDA. Prior to joining FDA in September, 1983, Dr.
Laughren was affiliated with the VA Medical Center in Providence,
RI, and was on the faculty of the Brown University Program in
Medicine. He received his medical degree from the University of
Wisconsin in Madison, Wisconsin, and also completed residency
training in psychiatry at the University of Wisconsin. Dr. Laughren
is board certified in general psychiatry. As Division Director for
the Division of Psychiatry Products, Dr. Laughren oversaw the
review of all psychiatric drug development activities conducted
under INDs and the review of all NDAs and supplements for new
psychiatric drug claims. He has authored and co-authored many
papers and book chapters on regulatory and methodological issues
pertaining to the development of psychiatric drugs and is a
frequent speaker at professional meetings on these same topics. Dr.
Laughren has received numerous awards for his regulatory
accomplishments.
This event is intended for institutional investors, sell-side
analysts, investment bankers, and business development
professionals only. Please RSVP in advance if you plan to attend,
as space is limited. For those who are unable to attend in
person, a live webcast and replay of the event will be accessible
here.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva`s proprietary compounds include:
roluperidone (MIN-101), in Phase 3 clinical development for
schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in Phase 2b
clinical development for insomnia and major depressive disorder
(MDD); MIN-117, planned to begin Phase 2b clinical development for
MDD in early 2018; and MIN-301, in pre-clinical development for
Parkinson`s disease. Minerva`s common stock is listed on the
NASDAQ Global Market under the symbol "NERV." For more
information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the potential
of the diagnosis and treatment of negative symptoms in
schizophrenia and other diseases; the timing and scope of future
clinical trials and results of clinical trials; the timing and
outcomes of future interactions with U.S. and foreign regulatory
bodies; our ability to successfully develop and commercialize our
therapeutic products. These forward-looking statements are
based on our current expectations and may differ materially from
actual results due to a variety of factors including, without
limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301
will advance further in the clinical trials process and whether and
when, if at all, they will receive final approval from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies and for which indications; whether any of our therapeutic
product discovery and development efforts will be successful;
management’s ability to successfully achieve its goals; our ability
to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Annual Report on
Form 10-K for the year ended December 31, 2017, filed with
the Securities and Exchange Commission on March 12,
2018. Copies of reports filed with the SEC are
posted on our website at www.minervaneurosciences.com. The
forward-looking statements in this press release are based on
information available to us as of the date hereof, and we disclaim
any obligation to update any forward-looking statements, except as
required by law.
Contact:William B. BoniVP, Investor
Relations/Corp. CommunicationsMinerva Neurosciences, Inc.(617)
600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2024 to May 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From May 2023 to May 2024